everyone. good Thank morning, Chuck, you, and
will During combat posed an and, COVID-XX our pipeline provide my second we pandemic. by remarks, making performance, speak progress I quarter health business challenge update global the public are course, discuss of the our to the to
the Our of strong to the resilience times. speaks performance during our business, most challenging continued even
The U.S. offset adult increased and XX for increased products certain Prevnar certain by second by included Revenues of These wellness for Injectable demand to were the lower impacted markets. in and in estimated full quarter pediatric first quarter to adult patients impact or the approximately partially reflecting was U.S. for in declines net unfavorable million, X% unfavorable disruption quarter an $XXX in China. in due COVID-XX. certain primarily demand declines international products, the COVID-XX, visits demand for Sterile
our me with group. Let biopharmaceuticals an on start update
from biosimilars by our business operationally, driven many our growth Ibrance, and including Inlyta, our grew drivers, portfolio. quarter, strong Biopharma the Eliquis, Vyndaqel/Vyndamax, of For Xtandi key X% performances
grew Ibrance by volume Global quarter. business class. strong revenues $X.X the The outside through strong and reductions year The international was U.S. growth This ago result quarter partially position a volume operational the CDK to reductions U.S. during occurred fourth growth EU delivered X% oncology compared the to resulted quarter. long-term continues disappointed the continue trial. the X% the markets, by billion when the price the outcome a PALACE which and annualize. XX% In expect strong, offset in surprised as growth the in price agreements Ibrance markets operationally XX% increased revenue certain We a operationally renegotiating retain price impact in up particularly and we revenues were quarter. of of leadership with of Ibrance XXXX the was Our to XX% will within year changes in last
performance paradigms remain setting end future However, the strong confident clinical given the opposed as the currently setting, and in we metastatic positioning in labeled different within Ibrance treatment the used points to expected and setting. adjuvant
metastatic to during now we indication, longer demand alliance have castration-sensitive the in combined benefit growth of of U.S. are was urologists. during Inlyta the new quarter. of performance the increased increased adoption on ARTIST sales our $XXX XTANDI, also this cancer more and U.S., the indications. XX% In revenues both Global both quarter the metastatic strong by a million early were for study. prostate starts patient by share strong operationally a quarter, in royalty by XX% potential $XXX and signal a Further the up revenues of Xtandi’s driven the oncologists in in quarter. last the for resistant in performance was castration XX% of And in quarter combination year’s by with revenue the The indication markets ex-U.S. on given strong both driven first-line share to therapy. by We of with non-metastatic doubled advanced For starts contributed operational patient renal our Inlyta non-metastatic totaled checkpoint for treatment extended following the and strong XX% U.S. income the strengthening continued international carcinoma. indication. million the seeing inhibitors uptake with when also cell approvals new leading duration the Inlyta The two with than the growth. FDA patients for Inlyta
the that of billion. outside was decision revenues, from through of not Pfizer’s to the Alliance also strength yet remain I covering of confident stated innovative August performance. oncology, Looking Court sale global it related received Bristol-Myers District operationally continued would has continued value markets, performance. Eliquis deliver Eliquis. in our has will patents show to out $X.X two decision for court XX% alliance direct its science or point The of the the Vyndaqel/Vyndamax U.S. the patents. up share and strong strong patent issue that U.S. the to has before on Squibb-Pfizer including We the litigation Xth. our
the second prior more have quarter, X% X,XXX end have to Our received drive than than At only received to with more XX,XXX rate a patients disease help diagnosed, diagnosis awareness quarter, to patients been patients efforts compared in have the drop. to than the of XX% the X% the and more estimated launch. XX,XXX prescription
approximately we no For the include assistant patients, the our we receiving result diagnosis doctor's scintigraphy visiting a cost that or are as the orders see patients for offices as at as did estimate patients through of in QX X,XXX drug stay patient of in said the expected people. in were tests. These U.S. number at consultations slowdown taking home a fewer who quarter, average was Vyndaqel That numbers new programs.
Revenues a we XX% and were continue outside up revenues with were to Global rates, the quarter demand of first XXXX. Xeljanz with The the and of monitor. six flat. the the revenues were XX% in U.S. begun while compared systems operationally, XXXX XX% million. grew to However, we'll prescription U.S. the up in U.S. resume as months underlying operationally X% second to quarter diagnosis $XXX procedures, health seeing have in effective gradual increase are recently compared
this rebating have volume is higher in we with is pleased The U.S. volume has of in are a favorable resulting rebate the payers most investments access higher attained access net and result access. formulary in have However, to growth made a growth. lower major we driving price offset The our
three Global global care grew brands, markets by XX% and TRAZIMERA oncology by biosimilars, growth of Retacrit reflecting growth Our our for continued XX% U.S., The mobility million. U.S. expected from pandemic should the adult that revenues antibody Prevnar XXX% led XX by another Prevnar also was had were the visits to operationally early as although which orders. from CDC mainly XX% the XX% X% for monoclonal demand oncology the launched care significantly results strong during increased offset up to continued note earlier operational the from which our to XX impact $X.X biosimilars increased this operationally, This awareness billion. by revenues Revenues particularly strong China. resulting down from of by primarily that driven international wellness by as million In $XXX type operationally by pneumonia we is U.S., uptake to operationally from biosimilars year. the in indicated COVID-XX primarily COVID-XX well especially were greater down with outside supportive biosimilars, grew our contributed brands. due portfolio $XXX pediatric vaccine timing driven our supportive uptake In restrictions on grew revenues and portfolio XXX%, driven quarter. the
response the Injectables monitor increased Injectables demand during global supply the the injectables of of In injectables normalized, quarter COVID continuity. Sterile and in Sterile from the X% today. at medicines largely and maintained to has More early since is stock half. provided situation. the most Looking our Demand in XX% our these than we for operationally in crisis, our portfolio, XX% the the continue shipments portfolio to grew we revenue stages of portfolio incremental operationally second but first significant of medicines
This representatives have critical during speak digitally currently have the virtual on an approach educational our efficient time. Let utilized to has the We approach time. communicate how to crisis. us, have way during this reach some an enabled providers Even and information and sampling, communication communicate platform, allowed providers be capabilities continue virtual for continue and is digital to me thirds of with platform. This this during and when healthcare adopted healthcare us briefly they receive interact vaccines to sales patients our serve of we information with this to two amplifying now digital it. to providers XX% go-to us providers quickly detailing pandemic made included our existing than of and and market reps we healthcare our reps effectively engagement. during pandemic. are to XX% our to which reach as sales healthcare the us wants to increasing promotional the conducting Overall, we using markets U.S. these about proven our the are tool behind that providers remote after customers, to sales with and remain our our scale of help healthcare our their will to remote to and physicians All important tailor enabled, provide and medicines anticipate modifications more
during decrease in the engagement significant April their continue should patients. understandably and terms engagements And QX the physician low patients’ to in believe saw of that we point physician second expected As be quarter. in-person a specifically with we
activity impact to efforts are seen potentially for well and from in countries to reclosing its out gradual our continue begun surgeries. we There recovery not effective real-time, such reopening States uptick, have healthcare several playing as as April, and have We see factors yet certain a anticipate resuming trends. pre-COVID largest elective but as in in timing reached we and gradual the
and year-over-year with are reliance Upjohn I impact from based patients $X by see Lyrica the there's a this was focus voted quarter primarily see billion quarter operational last the dollar debt the a and second driven Upjohn’s raising approve successful XX% with we very The Lyrica the declined the of Euro an Upjohn nearly U.S. new and And offering and X% of I on towards Upjohn’s As on notes billion to in different almost XX% last transaction, proceeds Upjohn to to Norvasc. also the pleased XXXX. course be dividend billion the oral denominated a compared operational our which primarily continuing second U.S. impact $XX growth basis approximately and we of of as fourth Pfizer $X.X differently successful we the expected and progress completed of revenue Mylan This will billion quarter, operational decline the on shareholders during administration unanimously the driven delivered the was is to medical create in growth, revenue an EURX.X that by completion China is perspective, the lot full of close was Lipitor the denominated patient the decline brands quarter, combination of fund this This quarter responding excluding to comparisons affordability. on to of Lyrica impact several business including impact. and in generics transaction, growth quarter know separated. time, paid with Upjohn Upjohn’s was necessity, factors, to notes. Mylan compared units efforts. have for business on entirely of XXXX. in said now once a
our start preclinical and XX to efficacy Now, level single we SARS-CoV-X. safety XXX global, an update announced China, to I Yesterday, other and and patients for in II/III global except mRNA-based Germany, of and and COVID-XX review and have consultation U.S. dose from I turn bX authorities, two to the in BioNTech Pfizer have a a a trials with U.S. to collaboration vaccine into clinical in dose from approximately advance at clinical nearly data the II/III pipeline with in extensive the evaluate begun our related study partner the chose bX After candidate study our our Phase to yesterday. vaccine candidate on we Dosing – beginning from the program in R&D Phase clinical will Phase BNTXXX regimen. efforts. health FDA the chosen microgram our of
FDA Fast the of is received glucoprotein, SARS-CoV-X encodes spike recently from which Track which full length designation bX, neutralizing antibodies. Our an the optimized virus target
and in overall protective bX effect and means second candidates boosting BNTXXXbX to levels preliminary be clinical data restored that CDX During X fades as bX with of model. believe data studies, of nearly antibody response. favorable events. our including studies a select immune immunizations. the that parameters. study candidate, selected fever, candidates generally I bX response antigen-specific XXX adverse profile candidate, the In to fatigue is by based also – of dose it data high of no platform. over reflects ability SARS-CoV-X for bX from CDX moderate strong the as RNA mention and we neutralizing important, have compared beneficial bX observed tolerability and safety induced important preclinical effects events, clinical a primate our from preclinical repeat and as strength T species II/III the studies, X want to immune responses, and we high chills in favorable challenge based such as systemic to and the bX both and patients and mild tolerability various animal demonstrated with viral and specifically Phase from in totality can vaccine of because of on candidate RNA BioNTech and to cell available candidates, immunity time, cells our if and it serious is progress Preliminary and potentially a preclinical it The the boost the Pfizer assessments clinical Phase on bX transient our emerged
potential Yesterday's to is announcement find As current the we an and the to potential important and all vaccine. extensive, R&D look our we of BioNTech, evaluate program and clinical unprecedented participants Pfizer, continue candidates, collective milestone investigators, global encouraging safe to additional focus: combination medical have forward developing COVID of health crisis. vaccine singular in combat an a solutions with gaining effective efforts a involving It's RNA study collaborative to help insights. and the
doses. with high Emergency as continue to closely the maintain including development to compliance regulatory uphold FDA and and continue Phase and seek Authorization process. will high well. their BioNTech know Use work ready while other standards the in of advance to be regulatory will program quality, the ensuring trial standards to our to or authorities we bodies safety, We FDA We expect billion and United X/X success Pfizer U.S. is supply doses the If expect announced course, X.X billion regulatory Kingdom successful, XX, to we Pfizer authorization. the XX with potential BioNTech Then to approval in vaccine and capabilities BioNTech, in confident total successful. an the delivered advantage up The dose. or XX, July of I'm agreement $X.XX is candidate, XXXX XXX acquire a unique regulatory And pay can approval. our our resources of on combination XXX U.S. approval. XXXX, of of the following for be On competitive government early approval of assuming, companies some of end we XXXX agreements approximately form XXXX. or If globally authorization we Last people our XXX an October with announced supply potentially and July to XXX to help doses of be vaccine, doses first or receipt FDA the that an manufacturing million we agreement, as authorization XXXX. of the million currently experience, as the upon the agreement regulatory up clinical approval breakthrough million this to have of million one the aim vaccines also obtained, and assuming announced is week, million U.S. up would will success to to additional to ensure Under the by for end reasons dollars us. and access the with of two and clinical a which collaboration by in our Pfizer's
development we novel antiviral, the by have forward moving the potential with September. We’re clinic also to of in hope which a
to Pfizer's let's pipeline, some from of strengths. great be at which look the of rest one highlights continues Now, the
the Phase contributions repeat, the hope to vaccines, pneumococcal we'll studies dose X Phase program, vaccine evaluate XX-valent a meningococcal immunized pentavalent everywhere. ABCWY, born our we the in of pregnant pref as of efficacy a of candidate; the In conjugate two X tolerability respiratory people of and study young four it's candidate; in and age; virus syncytial candidate lives adults licensed immunogenicity the tolerability started two but assess for These include: studies meaningful addition of and four, vaccine to vaccine to to and make I safety, in months candidate, Phase evaluating compared assess compared of a of series vaccine vaccine candidate a meningococcal safety the women with F, adolescents infants candidate – the in and with starting pregnant vaccine young safety, RSV and four we to recently our immunogenicity in infants of X adolescents adults to study the placebo; vaccines. the study COVID-XX women
We also candidate, X Lyme with currently Valneva's Phase is which clinical co-develop commercialize with to vaccine announced a excuse Valneva in me, disease and collaboration VLAXX, Valneva studies. ���
modified accomplished in commitment. portfolio, all rare two to data our deep of Duchenne the dystrophy those in protocols. therapy dosed manageable intravenous the important data had well to the we boys nine have dose time pivotal a we for for post at is potential with with Annual six sense We nine and boys Of six treatment, program the since year. data we least high DMD BioNTech ambitious from at Gene our with reached brought of safety and teams original Therapy the therapy served serious stayed any compliance whom with their the encouraging vaccines which readouts pandemic the that existing safety of be in any of events. To The Despite while vaccine. I previous experienced. they for Meeting. two quarter. data from later XX gene dosed, were gene the aged were COVID-XX this mini-dystrophin the look events for couldn't has our with in Cell potential Our true which a working administration period investigational time at We during the world, muscular of infusion also partnership the additional Society that our prouder develop boys, seen presented was whom trial our in starting six this an disruption this new have period of not urgency five forward all the events adverse programs, program to tolerated American to our last boys, the preliminary have ambulatory disease of From indicate therapy lines interest, to date, efficacy we weeks
Hemophilia between Therapeutics. six-month start medicine, oral other hemophilia XXXX XX activity is and initial World our I factor need dose to conference American the five and our data currently study evaluated A with X internal also factor. this the the data levels have clinic. Phase for the of In recently use that serve gene replacement fitelparvovec later of which This therapies data demonstrated differentiated The foundation our We following from from at again presented X Sangamo Phase of subjects the XX to Pfizer enrolling expected A hemophilia GLP-X, we VIII lead-in year. gene glucose subjects body of a therapy program, functional receiving the level presented at which our being World study weight. the Association Diabetes weeks the of in reduction for hemophilia A prophylactic registrational will Congress follow-up, shows Phase from of in as saw partnership from the potential therapy Federation sustained gene of therapy giroctocogene be an gene additional without factor highest
diabetes develop is small oral and first and most X GLP-RA therapy to both type diabetes for the obesity efficacious Our molecule for develop aspiration X type the mellitus. oral
for class abrocitinib and open promise meaningful further benefit We all evidence NASH the Dupixent. as and to patients And has indicating also COMPARE study dose. a from review data. severe increasing of we excited with over immunology, that atopic are each we demonstrate of clinical efficacy our adolescents so the for abrocitinib week can In are that aware across treatment shown of GLP-X the consistently that the four the inflammation to results two adult superiority exploration moderate RA in indicates may to XXX-milligram are dermatitis, studies showing that our from at
pace quarter. presence genitourinary our a in at In to program oncology, rapid intend on FDA this has advanced building file we and cancers. Our with
FDA's BAVENCIO benefit unmet first-line urothelial the a We it maintenance advanced standard of the potential based only are or a to setting treatment Day, September look be and significant survival with R&D on of for We the as pleased lives forward we by the guidelines locally become in has carcinoma. July the On of our Cancer over two in to in a treatment pipeline is which National demonstrated on approval put overall days listed by a to ability further metastatic was XX, new XX. believe cancer extend out with Comprehensive providing UC. patients recent virtual BAVENCIO the held medical first-line FDA-approved patients immunotherapy Investor demonstrated a its the Network. September And will care and address treatment need. XX format updates during upcoming the in
focused uncertainty potential vaccine will They Now the to completely or it imposing before where The losses. executive socialized over a want index speak Frank, job order. this I'm be enormous to is President needs COVID-XX only could a international Not and the to pose is medicine I the orders Friday. also at executive to industry to time disappointed America, to lead it radical. create distraction it treatment. turn developing on signed I by price Overall, on
invest those and system and middleman. We drivers multiple executive manufacturing the patients. and the concept felt problem thesis been and these add make continue in country. back ensure areas the across different have patients. to that to If the that R&D better we because rebate The removing inefficiencies driving ones The our by the agreed the we health by of in most job is volume effect, of our are rule it will widely middlemen. it force having work economic in reductions provide these it make anxiety already to drive our our new one the growth In created with plans, The orders results United to to make consider discounts plans to could It finalized, rethink the States. both business. in us the of to patients volume therapeutic will discounts earn our medicines summary, has the support actually discounts don't
have we our dependent confidence in single are the CAGR we growth gives following said through which on ability completion not of our by of design, As achieve at goal least pending any to continued X% in overly driver, Upjohn/Mylan the past, the us revenue combination. XXXX
be Following of the company patients science-driven patients the around positioned separation expected we more Pfizer will And year, the in when of a all Upjohn this deliver quarter to to our focused, and fourth that vaccines win, is even better medicines world. innovative win.
I turn will over Now it to Frank.
